DAPTOMYCINE HIKMA PHARMA 350 mg, powder for solution for injection/for infusion bottle, 15 ml
Active ingredients: (2S)-daptomycin
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Powder for solution for injection or infusionbottle, 15 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- DAPTOMYCINE HIKMA PHARMA 350 mg, poudre pour solution injectable/pour perfusion
- Pharmaceutical form
- poudre pour solution injectable ou pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre de 15 ml
- Marketing authorisation holder
- HIKMA FARMACEUTICA (PORTUGAL)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 26 Feb 2025
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65568538CIP75510112CIP133400955101123Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DAPTOMYCINEpoudre | 350 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.